HLA-DRB5 Antikörper (AA 43-70) (PE)

Produktnummer ABIN1902460

Produktdetails anti-HLA-DRB5 Antikörper (PE)

Target: HLA-DRB5 (Major Histocompatibility Complex, Class II, DR beta 5 (HLA-DRB5))

Bindungsspezifität: AA 43-70

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HLA-DRB5 Antikörper ist konjugiert mit PE

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Spezifität: This HLA-DRB5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 43-70 amino acids from the Central region of human HLA-DRB5.

Aufreinigung: Affinity purified

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Approved: ELISA, IHC, WB

Usage: The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested.

Kommentare:

Target Species of Antibody: Human

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: PBS, no preservatives added

Konservierungsmittel: Without preservative

Handhabung: Aliquot to avoid repeated freezing and thawing.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short term: store at 4°C. Long term: aliquot and store -20°C for up to 6 months. Avoid freeze-thaw cycles. Protect from light.

Haltbarkeit: 6 months

Details zu HLA-DRB5

Target: HLA-DRB5 (Major Histocompatibility Complex, Class II, DR beta 5 (HLA-DRB5))

Andere Bezeichnung: HLA-DRB5 (HLA-DRB5 Produkte)

Synonyme: HLA-DRB antikoerper, major histocompatibility complex, class II, DR beta 5 antikoerper, HLA-DRB5 antikoerper

Hintergrund: Name/Gene ID: HLA-DRB5

Synonyms: HLA-DRB5, DR-9, DR beta-5, Dw2, HLA-DRB, Human leucocyte antigen DRB5, MHC class II antigen DRB1*9, MHC class II HLA beta chain, MHC HLA-DR-beta chain, Leukocyte antigen class II, DR2-beta-2, DR9, MHC class II antigen DRB5

Gen-ID: 3127

Pathways: T-Zell Rezeptor Signalweg, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints